EE668 Empagliflozin for the Treatment of Adult Patients With Symptomatic Chronic Heart Failure With Reduced Ejection Fraction (HFREF): A Cost-Effectiveness Analysis From the Italian NHS Perspective
Dec 1, 2022, 00:00
10.1016/j.jval.2022.09.907
https://www.valueinhealthjournal.com/article/S1098-3015(22)03111-4/fulltext
Title :
EE668 Empagliflozin for the Treatment of Adult Patients With Symptomatic Chronic Heart Failure With Reduced Ejection Fraction (HFREF): A Cost-Effectiveness Analysis From the Italian NHS Perspective
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)03111-4&doi=10.1016/j.jval.2022.09.907
First page :
Section Title :
Open access? :
No
Section Order :
10451